<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Kamada — News on 6ix</title>
    <link>https://6ix.com/company/kamada</link>
    <description>Latest news and press releases for Kamada on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 31 Mar 2026 04:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/kamada" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68358e5f78dffbe2df101310.webp</url>
      <title>Kamada</title>
      <link>https://6ix.com/company/kamada</link>
    </image>
    <item>
      <title>Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders</title>
      <link>https://6ix.com/company/kamada/news/kamada-updates-on-withholding-tax-procedures-on-previously-announced-cash-dividend-to-shareholders</link>
      <guid isPermaLink="true">https://6ix.com/company/kamada/news/kamada-updates-on-withholding-tax-procedures-on-previously-announced-cash-dividend-to-shareholders</guid>
      <pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
      <description>REHOVOT, Israel and HOBOKEN, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (the “Company”) (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical</description>
    </item>
    <item>
      <title>Kamada Announces FDA Approval of its Plasma Collection Center in San Antonio, Texas</title>
      <link>https://6ix.com/company/kamada/news/kamada-announces-fda-approval-of-its-plasma-collection-center-in-san-antonio-texas</link>
      <guid isPermaLink="true">https://6ix.com/company/kamada/news/kamada-announces-fda-approval-of-its-plasma-collection-center-in-san-antonio-texas</guid>
      <pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
      <description>San Antonio Center Cleared to Commence Commercial Sales of Normal Source PlasmaState of the Art Facility has Annual Collection Capacity of Approximately</description>
    </item>
    <item>
      <title>Kamada Declares Cash Dividend of $0.25 Per Share, to be Paid in Accordance with an Adopted Annual Cash Dividend Policy</title>
      <link>https://6ix.com/company/kamada/news/kamada-declares-cash-dividend-of-dollar025-per-share-to-be-paid-in-accordance-with-an-adopted-annual-cash-dividend-policy</link>
      <guid isPermaLink="true">https://6ix.com/company/kamada/news/kamada-declares-cash-dividend-of-dollar025-per-share-to-be-paid-in-accordance-with-an-adopted-annual-cash-dividend-policy</guid>
      <pubDate>Wed, 11 Mar 2026 04:00:00 GMT</pubDate>
      <description>Company Reports Record Revenue and Profitability for Full-Year 2025 REHOVOT, Israel and HOBOKEN, N.J., March 11, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:</description>
    </item>
    <item>
      <title>Kamada Reports Record Top- and Bottom-line 2025 Financial Results and Affirms 2026 Guidance Representing Continued Double-Digit Organic Profitable Growth</title>
      <link>https://6ix.com/company/kamada/news/kamada-reports-record-top-and-bottom-line-2025-financial-results-and-affirms-2026-guidance-representing-continued-double-digit-organic-profitable-growth</link>
      <guid isPermaLink="true">https://6ix.com/company/kamada/news/kamada-reports-record-top-and-bottom-line-2025-financial-results-and-affirms-2026-guidance-representing-continued-double-digit-organic-profitable-growth</guid>
      <pubDate>Wed, 11 Mar 2026 04:00:00 GMT</pubDate>
      <description>2025 Full Year Revenue of $180.5 Million, up 12% Year-over-Year; Adjusted EBITDA of $42.0 Million, up 23% Year-over-Year; Net Income of $20.2 Million, up 40%</description>
    </item>
    <item>
      <title>Kamada to Announce Fiscal Year and Fourth Quarter 2025 Financial Results on March 11, 2026</title>
      <link>https://6ix.com/company/kamada/news/kamada-to-announce-fiscal-year-and-fourth-quarter-2025-financial-results-on-march-11-2026-6</link>
      <guid isPermaLink="true">https://6ix.com/company/kamada/news/kamada-to-announce-fiscal-year-and-fourth-quarter-2025-financial-results-on-march-11-2026-6</guid>
      <pubDate>Wed, 04 Mar 2026 05:00:00 GMT</pubDate>
      <description>Company to Host Conference Call at 8:30am ET REHOVOT, Israel, and HOBOKEN, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA),</description>
    </item>
    <item>
      <title>Kamada Provides 2026 Annual Guidance of $200 - $205 Million in Revenues and $50 - $53 Million of Adjusted EBITDA, Representing Double-Digit Growth and Affirms 2025 Financial Guidance</title>
      <link>https://6ix.com/company/kamada/news/kamada-provides-2026-annual-guidance-200-205-million-revenues-and-50-53-million</link>
      <guid isPermaLink="true">https://6ix.com/company/kamada/news/kamada-provides-2026-annual-guidance-200-205-million-revenues-and-50-53-million</guid>
      <pubDate>Wed, 07 Jan 2026 05:00:00 GMT</pubDate>
      <description>2026 Guidance Represents Year-Over-Year Increase of 13% in Revenues and 23% in Adjusted EBITDA Based on Mid-Point of 2025 Annual Guidance2026 Annual Guidance</description>
    </item>
    <item>
      <title>Kamada Announces a $10-$14 Million Extension of Canadian Supply Tender</title>
      <link>https://6ix.com/company/kamada/news/kamada-announces-10-14-million-extension-canadian-supply-tender-2025-12-18</link>
      <guid isPermaLink="true">https://6ix.com/company/kamada/news/kamada-announces-10-14-million-extension-canadian-supply-tender-2025-12-18</guid>
      <pubDate>Thu, 18 Dec 2025 05:00:00 GMT</pubDate>
      <description>Company Awarded Extension to Existing Supply Tender Relating to its Portfolio of Four Specialty Plasma-Derived ProductsSupply Extension Secures Ongoing Sales</description>
    </item>
    <item>
      <title>Kamada Announces Discontinuation of its Phase 3 Inhaled AAT Clinical Trial; Reiterates 2025 Full-Year Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2026</title>
      <link>https://6ix.com/company/kamada/news/kamada-announces-discontinuation-its-phase-3-inhaled-aat-clinical-trial-reiterates</link>
      <guid isPermaLink="true">https://6ix.com/company/kamada/news/kamada-announces-discontinuation-its-phase-3-inhaled-aat-clinical-trial-reiterates</guid>
      <pubDate>Mon, 08 Dec 2025 05:00:00 GMT</pubDate>
      <description>Based on the Results of a Planned Interim Futility Analysis the Inhaled AAT Trial is Unlikely to Demonstrate a Statistically Significant Benefit in its</description>
    </item>
    <item>
      <title>Kamada Reports Strong Third Quarter and Nine Month 2025 Financial Results with over 30% Year-over-Year Profitability Growth</title>
      <link>https://6ix.com/company/kamada/news/kamada-reports-strong-third-quarter-and-nine-month-2025-financial-results-over-30</link>
      <guid isPermaLink="true">https://6ix.com/company/kamada/news/kamada-reports-strong-third-quarter-and-nine-month-2025-financial-results-over-30</guid>
      <pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
      <description>Third Quarter Revenues of $47.0 Million, up 13% Year-over-Year, and Adjusted EBITDA of $11.7 Million, up 34% Year-Over YearNine Month Revenue of $135.8</description>
    </item>
    <item>
      <title>Kamada Announces First Patient Enrolled into an Investigator-Initiated Clinical Trial of CYTOGAM® to Prevent Cytomegalovirus in Kidney Transplantation</title>
      <link>https://6ix.com/company/kamada/news/kamada-announces-first-patient-enrolled-investigator-initiated-clinical-trial</link>
      <guid isPermaLink="true">https://6ix.com/company/kamada/news/kamada-announces-first-patient-enrolled-investigator-initiated-clinical-trial</guid>
      <pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
      <description>Post Marketing Study to Evaluate the Role of CYTOGAM in the Reduction of Risk of Late CMV Disease Following the Conclusion of Standardly Prescribed Antiviral</description>
    </item>
    <item>
      <title>Kamada to Announce Third Quarter and Nine Months Ended September 30, 2025 Financial Results on November 10, 2025</title>
      <link>https://6ix.com/company/kamada/news/kamada-announce-third-quarter-and-nine-months-ended-september-30-2025-financial</link>
      <guid isPermaLink="true">https://6ix.com/company/kamada/news/kamada-announce-third-quarter-and-nine-months-ended-september-30-2025-financial</guid>
      <pubDate>Mon, 03 Nov 2025 05:00:00 GMT</pubDate>
      <description>Company to Host Conference Call at 8:30am ET REHOVOT, Israel and HOBOKEN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a</description>
    </item>
    <item>
      <title>Kamada to Present at the Stifel 2025 Healthcare Conference</title>
      <link>https://6ix.com/company/kamada/news/kamada-present-stifel-2025-healthcare-conference-2025-10-29</link>
      <guid isPermaLink="true">https://6ix.com/company/kamada/news/kamada-present-stifel-2025-healthcare-conference-2025-10-29</guid>
      <pubDate>Wed, 29 Oct 2025 04:00:00 GMT</pubDate>
      <description>REHOVOT, Israel and Hoboken, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a</description>
    </item>
    <item>
      <title>Kamada to Participate in Upcoming September Investor Conferences</title>
      <link>https://6ix.com/company/kamada/news/kamada-participate-upcoming-september-investor-conferences-2025-09-02</link>
      <guid isPermaLink="true">https://6ix.com/company/kamada/news/kamada-participate-upcoming-september-investor-conferences-2025-09-02</guid>
      <pubDate>Tue, 02 Sep 2025 04:00:00 GMT</pubDate>
      <description>REHOVOT, Israel, and HOBOKEN, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a</description>
    </item>
    <item>
      <title>Kamada Reports Strong Second Quarter and First Half 2025 Financial Results with 11% Year-Over-Year 6-Month Top Line Growth and a 35% Increase in Profitability; Raises Full-Year Profitability Guidance</title>
      <link>https://6ix.com/company/kamada/news/kamada-reports-strong-second-quarter-and-first-half-2025-financial-results-11-year</link>
      <guid isPermaLink="true">https://6ix.com/company/kamada/news/kamada-reports-strong-second-quarter-and-first-half-2025-financial-results-11-year</guid>
      <pubDate>Wed, 13 Aug 2025 04:00:00 GMT</pubDate>
      <description>First Half 2025 Total Revenues were $88.8 Million, up 11% Year-over-Year; Revenues for 2025 Second Quarter were $44.8 Million, up 5% Year-over-Year First Half</description>
    </item>
    <item>
      <title>Kamada Announces FDA Approval of its Plasma Collection Center in Houston, Texas</title>
      <link>https://6ix.com/company/kamada/news/kamada-announces-fda-approval-its-plasma-collection-center-houston-texas-2025-08-11</link>
      <guid isPermaLink="true">https://6ix.com/company/kamada/news/kamada-announces-fda-approval-its-plasma-collection-center-houston-texas-2025-08-11</guid>
      <pubDate>Mon, 11 Aug 2025 04:00:00 GMT</pubDate>
      <description>Houston Center Cleared to Commence Commercial Sales of Normal Source PlasmaState of the Art Facility has Annual Collection Capacity of Approximately 50,000</description>
    </item>
    <item>
      <title>Kamada to Announce Second Quarter and First Half Ended June 30, 2025 Financial Results on August 13, 2025</title>
      <link>https://6ix.com/company/kamada/news/kamada-announce-second-quarter-and-first-half-ended-june-30-2025-financial-results</link>
      <guid isPermaLink="true">https://6ix.com/company/kamada/news/kamada-announce-second-quarter-and-first-half-ended-june-30-2025-financial-results</guid>
      <pubDate>Wed, 06 Aug 2025 04:00:00 GMT</pubDate>
      <description>Company to Host Conference Call at 8:30am ET REHOVOT, Israel, and HOBOKEN, N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA),</description>
    </item>
    <item>
      <title>Kamada Confirms Continuous Global Business Operations and Products Availability Despite Recent Events in the Middle East</title>
      <link>https://6ix.com/company/kamada/news/kamada-confirms-continuous-global-business-operations-and-products-availability</link>
      <guid isPermaLink="true">https://6ix.com/company/kamada/news/kamada-confirms-continuous-global-business-operations-and-products-availability</guid>
      <pubDate>Tue, 17 Jun 2025 04:00:00 GMT</pubDate>
      <description>REHOVOT, Israel and HOBOKEN, N.J., June 17, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a</description>
    </item>
    <item>
      <title>Kamada Q1 Results: Double-Digit Growth, Company Reiterates Guidance As It Hits Multiple Milestones Including Plasma Business Expansion</title>
      <link>https://6ix.com/company/kamada/news/kamada-q1-results-double-digit-growth-company-reiterates-guidance-it-hits-multiple</link>
      <guid isPermaLink="true">https://6ix.com/company/kamada/news/kamada-q1-results-double-digit-growth-company-reiterates-guidance-it-hits-multiple</guid>
      <pubDate>Wed, 11 Jun 2025 04:00:00 GMT</pubDate>
      <description>By Meg Flippin Benzinga DETROIT, MICHIGAN - June 11, 2025 (NEWMEDIAWIRE) - Kamada Ltd. (NASDAQ: KMDA) recently reported earnings for the first quarter of</description>
    </item>
    <item>
      <title>Kamada Reports Strong First Quarter 2025 Financial Results with Year Over Year Top Line Growth of 17% and a 54% Increase in Profitability</title>
      <link>https://6ix.com/company/kamada/news/kamada-reports-strong-first-quarter-2025-financial-results-year-over-year-top-line</link>
      <guid isPermaLink="true">https://6ix.com/company/kamada/news/kamada-reports-strong-first-quarter-2025-financial-results-year-over-year-top-line</guid>
      <pubDate>Wed, 14 May 2025 04:00:00 GMT</pubDate>
      <description>Revenues for First Quarter of 2025 of $44.0 Million, Representing a 17% Year-over-Year IncreaseFirst Quarter Adjusted EBITDA of $11.6 Million, Up 54%</description>
    </item>
    <item>
      <title>Kamada to Announce First Quarter 2025 Financial Results on May 14, 2025</title>
      <link>https://6ix.com/company/kamada/news/kamada-announce-first-quarter-2025-financial-results-may-14-2025-2025-05-07</link>
      <guid isPermaLink="true">https://6ix.com/company/kamada/news/kamada-announce-first-quarter-2025-financial-results-may-14-2025-2025-05-07</guid>
      <pubDate>Wed, 07 May 2025 04:00:00 GMT</pubDate>
      <description>Company to Host Conference Call at 8:30am ET REHOVOT, Israel, and HOBOKEN, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a</description>
    </item>
  </channel>
</rss>